Is Bortezomib 2 mg a type of chemotherapy?
Bortezomib 2 mg is a proteasome inhibitor, which is a type of cancer treatment medicine. Cells contain proteasomes. They assist in the breakdown of proteins that the cell does not require. Bortezomib inhibits the proteasomes, causing proteins to accumulate inside the cell.
What is bortezomib injection used for?
The medication bortezomib is used to treat multiple myeloma (a type of cancer of the bone marrow). Bortezomib is also used to treat mantle cell lymphoma patients (fast-growing cancer that begins in the cells of the immune system). Bortezomib belongs to the class of medicines known as antineoplastic agents.
What are the Bortezomib 2 mg side effects?
- The injection site may cause dizziness
- lack of appetite
- or pain/redness.
- Common adverse effects include nausea, vomiting, and diarrhoea. Your doctor may recommend medication to prevent or alleviate nausea, vomiting, or diarrhoea in some circumstances. For more details Click Here.
How frequently is Bortezomib 2 mg administered?
VELCADE is given twice weekly for two weeks (Days 1, 4, 8, and 11), then a ten-day break from Days 12 to 21. Two further VcR-CAP cycles are indicated for patients who had a response at cycle 6. A minimum of 72 hours should elapse between VELCADE dosages.
Is bortezomib an oral medication?
Because bortezomib is supplied parenterally, the new medicine provides the convenience of oral administration. Initially, it was only accessible as an intravenous infusion, but it is now also available as a subcutaneous formulation.
How long does bortezomib stay in the body?
After a single dose, bortezomib is rapidly transported into tissues, with an initial plasma distribution half-life of fewer than 10 minutes and a terminal elimination half-life of more than 40 hours.
Is bortezomib linked to anaemia?
Side Effects that may occur. Nausea, diarrhoea, thrombocytopenia, neutropenia, peripheral neuropathy, lethargy, neuralgia, anaemia, leukopenia, constipation, vomiting, lymphopenia, rash, pyrexia, and anorexia are the most prevalent adverse effects of Velcade (reported at a 20% incidence in clinical research).